Oncogenomics: Prospects for the future

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 891-901

  Sakatani, Takashi ^a   Onyango, Patrick ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer epigenetics; Cancer genome; Cancer pathways; Chromatin modification; DNA microarray; Expression profiling; Genomics; Pharmacogenetics; Proteomics; RNAi

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; HISTONE ACETYLTRANSFERASE INHIBITOR; IMATINIB; RNA; TRANSFERASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CHROMATIN STRUCTURE; DNA METHYLATION; DNA MODIFICATION; DRUG MECHANISM; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MAPPING; GENE MUTATION; GENE SILENCING; GENOMICS; HEREDITY; HUMAN; REVIEW;

EID: 0348219060     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.891     Document Type: Review

References (79)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5, IARCPress, Lyon, France (2001).
2. Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 52(6), 1327-1334 (2003).
3. Remontet L, Esteve J, Bouvier AM et al. Cancer incidence and mortality in France over the period 1978-2000. Rev. Epidemiol. Sante Publique 51 (1 Pt 1), 3-30 (2003).
4. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
5. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291 (5507), 1304-1351 (2001).
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (5), 759-767 (1990).
7. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 278(5340), 1043-1050 (1997).
8. Redmond K. Treatment choices in advanced cancer: issues and perspectives. Eur. J. Cancer Care 7(1), 31-39 (1998).
9. Pennisi E. Behind the scenes of gene expression. Science 293(5532),1064-1067 (2001).
10. Verma M, Dunn BK, Ross S et al. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann. NY Acad Sci. 983, 298-319 (2003).
11. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3(2), 226-231 (1993).
12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3(6), 415-428 (2002).
13. Tycko B. Epigenetic gene silencing in cancer. J. Clin. Invest. 105(4), 401-407 (2000).
14. Schoenherr CJ, Levorse JM, Tilghman SM. CTCF maintains differential methylation at the Igf2/H19 locus. Nature Genet. 33(1), 66-69 (2003).
15. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9(1), 40-48 (1999).
16. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10(7), 687-692 (2001).
17. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386-389 (1998).
18. Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genet. 19(2), 187-191 (1998).
19. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nature Genet. 23(1), 62-66 (1999).
20. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13(15), 1924-1935 (1999).
21. Ng HH, Zhang Y, Hendrich B et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nature Genet. 23(1), 58-61 (1999).
22. Nguyen CT, Gonzales FA, Jones PA. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. Nucleic Acids Res. 29(22), 4598-4606 (2001).
23. Rice JC, Futscher BW. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 28(17), 3233-3239 (2000).
24. Kikuchi T, Itoh F, Toyota M et al. Aberrant methylation and histone deacetylation of cyclooxygenase-2 in gastric cancer. Int. J. Cancer 97(3), 272-277 (2002).
25. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14(3), 286-298 (2002).
26. Nguyen CT, Weisenberger DJ, Velicescu M et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62(22), 6456-6461 (2002).
27. Peters AH, O'Carroll D, Scherthan H et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107(3), 323-337 (2001).
28. Riggins GJ, Strausberg RL. Genome and genetic resources from the Cancer Genome Anatomy Project. Hum. Mol. Genet. 10(7), 663-667 (2001).
29. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
30. Eddy SR. Non-coding RNA genes and the modern RNA world. Nature Rev. Genet. 2(12), 919-929 (2001).
31. Cheok MH, Yang W, Pui CH et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet. 34(1), 85-90 (2003).
32. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 278(5340), 1054-1059 (1997).
33. Cui H, Cruz-Correa M, Giardiello FM et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299(5613), 1753-1755 (2003).
34. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 396(6712), 643-649 (1998).
35. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996).
36. Fodde R. The APC gene in colorectal cancer. Eur. J. Cancer 38(7), 867-871 (2002).
37. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2), 171-182 (2002).
38. Lidereau R, Eisinger F, Champeme MH et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 60(5), 1206-1210 (2000).
39. Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 93(11), 858-865 (2001).
40. Sidransky D, Tokino T, Hamilton SR et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256(5053), 102-105 (1992).
41. Sachidanandam R, Weissman D, Schmidt SC et al. International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409(6822), 928-933 (2001).
42. Issa JP. The epigenetics of colorectal cancer. Ann. NY Acad. Sci. 910, 140-153 (2000).
43. Eads CA, Lord RV, Wickramasinghe K et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61(8), 3410-3418 (2001).
44. Esteller M, Sparks A, Toyota M et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60(16), 4366-4371 (2000).
45. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 92(22), 1805-1811 (2000).
46. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96(22), 12754-12759 (1999).
47. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95(20), 11891-11896 (1998).
48. Laird PW. Oncogenic mechanisms mediated by DNA methylation. Mol. Med. Today 3(5), 223-229 (1997).
49. Virmani AK, Rathi A, Sathyanarayana UG et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res. 7(7), 1998-2004 (2001).
50. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19(53), 6102-6114 (2000).
51. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20(1), 325-334 (2002).
52. Druker BJ. ST1571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8(Suppl. 4), S14-S18 (2002).
53. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344(14), 1052-1056 (2001).
54. Barletta JM, Rainier S, Feinberg AP. Reversal of loss of imprinting in tumor cells by 5-aza-2′-deoxycytidine. Cancer Res. 57(1), 48-50 (1997).
55. Lubbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr. Top. Microbiol. Immunol. 249, 135-164 (2000).
56. Momparler RL, Eliopoulos N, Ayoub J. Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy. Adv. Exp. Med. Biol. 465, 433-446 (2000).
57. Lubbert M, Wijermans P, Kunzmann R et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114(2), 349-357 (2001).
58. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60(21), 6039-6044 (2000).
59. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 9(1), 40-48 (1999).
60. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765), 41-45 (2000).
61. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl Cancer Inst. 92 (15), 1210-1216 (2000).
62. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13(6), 477-483 (2001).
63. Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 8(Suppl. 4), S43-S48 (2002).
64. Lennon GG, Lehrach H. Hybridization analyses of arrayed cDNA libraries. Trends Genet. 7(10), 314-317 (1991).
65. Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, Mukai T. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc. Natl Acad. Sci. USA 88(21), 9523-9527 (1991).
66. Smiraglia DJ, Plass C. The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene 21(35), 5414-5426 (2002).
67. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3(6), 415-428 (2002).
68. Rhee I, Bachman KE, Park BH et al. DNMT1 and DNMT3b co-operate to silence genes in human cancer cells. Nature 416(6880), 552-556 (2002).
69. Adorjan P, Distler J, Lipscher E et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res. 30(5), E21 (2002).
70. Bowtell DD. Options available - from start to finish - for obtaining expression data by microarray. Nature Genet. 21 (Suppl. 1), 25-32 (1999).
71. Mills AA, Bradley A. From mouse to man: generating megabase chromosome rearrangements. Trends Genet. 17(6), 331-339 (2001).
72. Suzuki T, Shen H, Akagi K et al. New genes involved in cancer identified by retroviral tagging. Nature Genet. 32(1), 166-174 (2002).
73. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
74. Fire A. Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998).
75. Kamath RS, Fraser AG, Dong Y et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421(6920), 231-237 (2003).
76. Wu W, Hu W, Kavanagh JJ. Proteomics in cancer research. Int. J. Gynecol. Cancer 12(5), 409-423 (2002).
77. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577(2002).
78. Barry M, Bleackley RC. Cytotoxic T-lymphocytes: all roads lead to death. Nature Rev. Immunol. 2(6), 401-409 (2002).
79. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nature Rev. Immunol. 3(5), 413-425 (2003).